CD40LG and primary cutaneous marginal zone B-cell lymphoma: Indolent CBCL (PCFCL and PCMZL) are associated with 5‐year disease‐specific survival ≥ 95% [36, 163], though PCMZL with IgM expression has been associated with a less favorable course.